Media Center

Elastrin Presents at MedTech - Elastrin made a strong impression at MedTech Ahead 2025 by presenting its latest advancements in medical technology.

You may recognize elastin as a key ingredient in youthful skin, but did you know it’s also an essential component of your heart, lungs, and blood vessels? Recent advances in elastin preservation and regeneration research are unlocking promising pathways toward improved tissue health and longevity. Dr. Narendra Vyavahare is at the forefront of this exciting field. With a distinguished career focused on heart valve biomaterials, site-specific therapies, and extracellular matrix

May 2024 - #1 Amazon bestseller status has been awarded to an Elastrin co-founder's book Discovering the Nature of Longevity: Restoring the heart and body by targeting hidden stress . Douglas Mulhall's book is the first to reveal for a general audience the mysteries of elastin, along with the groundbreaking discoveries by Elastrin's CSO Dr. Naren Vyavahare. The book also chronicles co-invention by Dr. Charles Rice and Dr. Vyavahare of an antibody specific for damaged elastin

Revolutionizing healthcare with our advanced tissue repair technology! A journey through the groundbreaking technology DESTiNED of Elastrin Therapeutics. Lear more about the intricate world of elastin, the "elastic of life. We have developed a unique drug-loaded nanoparticle theraphy that can reverse tissue damage. Watch our drug-loaded nanoparticles selectively target damaged elastin, releasing therapeutic payloads for effective tissue repair while not binding to the healthy

This review explores how aging and diseases can lead to the progressive degradation of elastic fibers.

Elastrin Therapeutics Inc. closes $10M Funding Round

The cardiovascular system is an extremely dynamic environment, and its performance heavily relies on the synergies of its main players. The heart, arteries, and veins all must work together to provide the rest of the body with blood flow supplying sufficient oxygen and nutrients. Cardiovascular diseases (CVDs) emerge when one or more of these players become affected, and the effects are often dramatic: CVDs are the leading cause of death globally, representing over 30% of dea

CLEMSON, S.C. & BERLIN--( BUSINESS WIRE )--Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again. It is the latest addition to the growing portfolio of Kizoo Technology Capital, a rejuvenation biotech investor focused on reversing age-related damage on a cellular and molecular level. Elastrin’s lead asset is a nanoparticle conjugated with a novel monoclonal antibody for the trea

Clemson University researchers published pre-clinical proof of reversing in lab animals the leading cause of cardiovascular events in chronic kidney disease, vascular calcification, by using advanced nanoparticle and antibody therapy. Results were published recently in Scientific Reports, a Nature publication. CKD is an epidemic globally and until now no one has reversed the calcification that kills most of its victims, especially those on dialysis. The team, led by Clems